<bill session="117" type="s" number="5316" updated="2023-08-17T14:15:23Z">
  <state datetime="2022-12-20">REFERRED</state>
  <status>
    <introduced datetime="2022-12-20"/>
  </status>
  <introduced datetime="2022-12-20"/>
  <titles>
    <title type="display">Federal Clarity for Kratom Consumers Act</title>
    <title type="short" as="introduced">Federal Clarity for Kratom Consumers Act</title>
    <title type="official" as="introduced">A bill to protect access to kratom.</title>
  </titles>
  <sponsor bioguide_id="L000577"/>
  <cosponsors>
    <cosponsor bioguide_id="B001288" joined="2022-12-20"/>
  </cosponsors>
  <actions>
    <action datetime="2022-12-20">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2022-12-20" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="h" number="9634" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2023-08-17T14:08:27Z" status="Introduced in Senate">Federal Clarity for Kratom Consumers Act

This bill requires the Food and Drug Administration (FDA) to hold a hearing and establish a task force on the health and safety of products with kratom (an herbal substance that produces opioid- and stimulant-like effects). It also prohibits the FDA from regulating kratom products in a manner that is more restrictive as compared to regulations for food, dietary supplements, or dietary ingredients.</summary>
</bill>
